Korean Journal of Pharmacognosy (생약학회지)

The Korean Society of Pharmacognosy (한국생약학회)
권호 표지

Enhancement of Anti-tumor Immunity by Administration of Macrolepiota procera Extracts

큰갓버섯 추출물의 종양면역 증진 효과

  • Han, Kyung-Hoon (Division of Clinical Research, Medical Institute, Seoul Medical Center) ;
  • Kim, Doh-Hee (Division of Clinical Research, Medical Institute, Seoul Medical Center) ;
  • Song, Kwan-Yong (Division of Clinical Research, Medical Institute, Seoul Medical Center) ;
  • Lee, Kye-Heui (Division of Clinical Research, Medical Institute, Seoul Medical Center) ;
  • Kang, Tae-Bong (Department of Biotechnology, Konkuk University) ;
  • Yoon, Taek-Joon (Department of Food & Nutrition, Yuhan University)
  • 한경훈 (서울의료원 의학연구소) ;
  • 김도희 (서울의료원 의학연구소) ;
  • 송관영 (서울의료원 의학연구소) ;
  • 이계희 (서울의료원 의학연구소) ;
  • 강태봉 (건국대학교 의료생명과학부) ;
  • 윤택준 (유한대학교 식품영양학과)
  • Received : 2011.12.05
  • Accepted : 2012.02.17
  • Published : 2012.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

To examine the potentiation of Macrolepiota procera extracts (MPE-4) to act as adjuvant enhancing the tumor specific anti-tumor immune response, tumor vaccine prepared by boiling (HK vaccine) admixed with MPE-4 and immunized in mice. Vaccination of mice with HK vaccine in combination with MPE-4 resulted in higher inhibition in tumor metastasis compared with the mice of HK vaccine alone treatment against live syngeneic tumor cell challenge. The splenocytes from mice immunized HK vaccine mixed with MPE-4 was able to elicit a stronger cytotoxic T lymphocyte (CTL) response as compared with HK vaccine alone. In addition, the splenocytes from MPE-4 admixed HK vaccine immunized mice secreted a higher concentration of Th1 type cytokine such as IFN-${\gamma}$, and GM-CSF. Furthermore, the adoptive transfer of splenocytes from mice immunized HK vaccine and MPE-4 led to a more robust anti-tumour response than the HK vaccine alone. Overall, these results indicate that MPE-4 is a good candidate adjuvant of anti-tumor immune response.

Keywords

References

  1. Burnet, F. M. (1970) The concept of immunological surveillance. Prog. Exp. Tumor Res. 13: 1-27.
  2. Rosenberg, S. A., Yang, J. C. and Restifo, N. P. (2004) Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915. https://doi.org/10.1038/nm1100
  3. Emens, L. A. (2006) Roadmap to a better therapeutic tumor vaccine. Int Rev Immunol. 25: 415-443. https://doi.org/10.1080/08830180600992423
  4. Gough, M. J., Melcher, A. A., Ahmed, A., Crittenden, M. R., Riddle, D. S., Linardakis, E., Ruchatz, A. N., Emiliusen, L. M. and Vile, R. G. (2001) Macrophages orchestrate the immune response to tumor cell death. Cancer Res. 61(19): 7240-7247.
  5. Schnurr, M., Scholz, C., Rothenfusser, S., Galambos, P., Dauer, M., Robe, J., Endres, S. and Eigler, A. (2002) Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res. 62: 2347-2352.
  6. Strome, S. E., Voss, S., Wilcox, R., Wakefield, T. L., Tamada, K., Flies, D., Chapoval, A., Lu, J., Kasperbauer, J. L., Padley, D., Vile, R., Gastineau, D., Wettstein, P. and Chen, L. (2002) Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 62: 1884-1889.
  7. Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Thery, C., Masurier, C., Flament, C., Pouzieux, S., Faure, F., Tursz, T., Angevin, E., Amigorena, S. and Zitvogel, L. (2001) Tumorderived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 7: 297-303. https://doi.org/10.1038/85438
  8. Ahmad, M., Rees, R. C. and Ali, S. A. (2004) Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol. Immunother. 53: 844-854.
  9. Seliger, B. (2005) Strategies of tumor immune evasion. Bio- Drugs 19: 347-354.
  10. Gutzmer, R., Li, W., Sutterwala, S., Lemos, M. P., Elizalde, J. I., Urtishak, S. L., Behrens, E. M., Rivers, P. M., Schlienger, K., Laufer, T. M., Eck, S. L. and Marks, M. S. (2004) A tumor-associated glycoprotein that blocks MHC class IIdependent antigen presentation by dendritic cells. J. Immunol. 173: 1023-3102.
  11. Ogino, T., Bandoh, N., Hayashi, T., Miyokawa, N., Harabuchi, Y. and Ferrone, S. (2003) Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin. Cancer Res. 9: 4043-4051.
  12. Witham, T. F., Villa, L., Yang, T., Pollack, I. F., Okada, H., Robbins, P. D. and Chambers, W. H. (2003) Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. J. Neurooncol. 64: 63-69.
  13. Cheuk, A. T., Chan, L., Czepulkowski, B., Berger, S. A., Yagita, H., Okumura, K., Farzaneh, F., Mufti, G. J. and Guinn, B. A. (2006) Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunol. Immunother. 55: 68-75. https://doi.org/10.1007/s00262-005-0674-5
  14. Copier, J. and Dalgleish, A. (2006) Overview of tumor cellbased vaccines. Int. Rev. Immunol. 25: 297-319. https://doi.org/10.1080/08830180600992472
  15. Prasad, S. J., Farrand, K. J., Matthews, S. A., Chang, J. H., McHugh, R. S. and Ronchese, F. (2005) Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of $CD4^{+}CD25^{+}$ regulatory T cells. J. Immunol. 174: 90-98.
  16. Korbelik, M. and Sun, J. (2006) Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol. Immunother. 55: 900-909. https://doi.org/10.1007/s00262-005-0088-4
  17. Yoon, T. J., Kim, J. Y., Kim, H., Hong, C., Lee, H., Lee, C. K., Lee, K. H., Hong, S. and Park, S. H. (2008) Anti-tumor immunostimulatory effect of heat-killed tumor cells. Exp. Mol. Med. 40: 130-144. https://doi.org/10.3858/emm.2008.40.1.130
  18. Berzofsky, J. A., Terabe, M., Oh, S., Belyakov, I. M., Ahlers, J. D., Janik, J. E. and Morris, J. C. (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113: 1515-1525.
  19. Miconnet, I., Koenig, S., Speiser, D., Krieg, A., Guillaume, P., Cerottini, J. C. and Romero, P. (2002) CpG are efficient adjuvants for specific CTL induction against tumor antigenderived peptide. J. Immunol. 168: 1212-1218.
  20. Kim, H. J. and Lee, I. S. (2004) Antimutagenic and cytotoxic effects of Korean wild mushrooms extracts. Korean J. Food Sci. Technol. 36: 662-668.
  21. Barros, L., Baptista, P., Correia, D. M., Morais, J. S. and Ferreira, I. C. (2007) Effects of conservation treatment and cooking on the chemical composition and antioxidant activity of Portuguese wild edible mushrooms. J. Agric. Food Chem. 55: 4781-4788. https://doi.org/10.1021/jf070407o
  22. Han, K.H., Kim, D. H., Song, K. Y., Jo, S. Y., Lee, S.W. and Yoon, T. J. (2010) Activation of innate immunity by Lepiota procera enhances antitumor activity. Kor. J. Pharmacogn. 41: 115-121.
  23. Ha, E. S., Hwang, S. H., Shin, K. S., Yu, K. W., Lee, K. H., Choi, J. S., Park, W. M. and Yoon T. J. (2004) Anti-metastatic activity of glycoprotein fractionated from Acanthopanax senticosus, involvement of NK-cell and macrophage activation. Arch. Pharm. Res. 27: 217-224. https://doi.org/10.1007/BF02980109
  24. Zhang, S., Li, W., Xia, Z. and Mao, Y. (2011) CD4 T cell dependent tumor immunity stimulated by dendritic cell based vaccine. Biochem. Biophys. Res. Commun. 413: 294-298. https://doi.org/10.1016/j.bbrc.2011.08.089
  25. Fields, R. C., Shimizu, K. and Mule, J. J. (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95: 9482-9487. https://doi.org/10.1073/pnas.95.16.9482
  26. Nouri-Shirazi, M., Banchereau, J., Bell, D., Burkeholder, S., Kraus, E. T , Davoust, J. and Palucka, K. A. (2000) Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J. Immunol. 165: 3797-803.
  27. Pandolfi, F., Cianci, R., Lolli, S. and Dunn, I.S., Newton, E. E., Haggerty, T.J., Boyl,e L.A. and Kurnick, J. T. (2008) Strategies to overcome obstacles to successful immunotherapy of melanoma. Int. J. Immunopathol. Pharmacol. 21: 493-500
  28. Song, S., Zhang, K., You, H., Wang, J., Wang, Z., Yan, C. and Liu, F. (2010) Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/ regulatory T cells in tumour. Clin. Exp. Immunol. 162: 75-83. https://doi.org/10.1111/j.1365-2249.2010.04226.x